Show simple item record

dc.contributor.authorCouñago, Felipe
dc.contributor.authorLópez Campos, Fernando
dc.contributor.authorMartínez Salamanca, Juan Ignacio 
dc.contributor.authorDel Cerro, Elia
dc.description.abstractThere is clinically relevant molecular heterogeneity in prostate cancer (PCa), but this biological diversity has had only a minimal impact on clinical practice. Treatment outcomes in patients with localised PCa are often highly variable, even among patients stratified to the same risk group or disease state based on standard clinical and pathological parameters. In recent years, the development of gene panels has provided valuable data on the di erential expression of genes in patients with PCa. Nevertheless, there is an urgent need to identify and validate prognostic and predictive biomarkers that can be applied across clinical scenarios, ranging from localised disease to metastatic castration-resistant PCa. The availability of such tools would allow for precision medicine to finally reach PCa patients. In this review, we evaluate current data on molecular biomarkers for PCa, with an emphasis on the biomarkers and gene panels with the most robust evidence to support their application in routine clinical
dc.rightsAtribución-NoComercial-SinDerivadas 3.0 España*
dc.subjectDNA repairspa
dc.subjectGene panelsspa
dc.subjectGenetic testingspa
dc.subjectGermline mutationspa
dc.subjectPrecision medicinespa
dc.subjectProstate cancerspa
dc.subjectProstate genomicsspa
dc.titleClinical Applications of Molecular Biomarkers in Prostate
dc.description.extent789 KBspa

Files in this item

1.- Clinical Applications of ...788.2KbPDFView/Open

This item appears in the following Collection(s)

Show simple item record

Atribución-NoComercial-SinDerivadas 3.0 España
Except where otherwise noted, this item's license is described as Atribución-NoComercial-SinDerivadas 3.0 España